Back to top

Analyst Blog

Allergan, Inc. (AGN - Analyst Report) recently received encouraging news when the US Food and Drug Administration’s (FDA) General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee unanimously recommended the approval of Juvéderm Voluma XC.

The company is looking to get Juvéderm Voluma XC, its injectable hyaluronic acid dermal filler, approved for cheek augmentation to correct age-related volume deficit in the mid-face.

Although the FDA is not bound to accept the recommendation of the advisory panel it does pay heed when reviewing new drug applications. The company noted that if approved Juvéderm Voluma XC will be the first and only dermal filler in the US for the above mentioned indication. The company expects to launch the drug in late 2013.

A few days back Allergan reported first quarter 2013 earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.96 per share. While earnings increased 18.1% from the year-ago quarter, revenues increased 8.3% to $1,459.6 million, above the Zacks Consensus Estimate of $1,443 million. Allergan now expects 2013 earnings of $4.70 - $4.76 per share as compared to the previous guidance of $4.75 - $4.83 per share. The latest guidance includes the impact of the acquisition of MAP Pharmaceutical.

Allergan currently carries a Zacks Rank #3 (Hold). Stocks that look better positioned at present include AbbVie (ABBV - Analyst Report) and Onyx Pharmaceuticals, Inc. . Both the stocks carry a Zacks Rank #2 (Buy). Isis Pharmaceuticals, Inc. (ISIS - Analyst Report) also looks well-positioned with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
SIGNET JEWE… SIG 116.37 +7.72%
CHYRONHEGO… CHYR 2.72 +5.84%
US SILICA H… SLCA 70.72 +4.00%
MALLINCKROD… MNK 80.11 +2.32%
RF MICRO DE… RFMD 11.76 +2.31%